The US Food and Drug Administration has granted a new approval to a checkpoint inhibitor combo developed by AstraZeneca (LSE: AZN), Imfinzi (durvalumab) plus Imjudo (tremelimumab), in lung cancer.
The combination therapy is approved for marketing for use against Stage IV non-small cell lung cancer (NSCLC), together with chemotherapy.
Imjudo is an anti-CTLA-4 antibody, a new kind of immunotherapy which provides a different way to unlock the body’s immune system to combat cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze